Ovid Therapeutics (NASDAQ:OVID – Get Free Report) and Nuvation Bio (NYSE:NUVB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
Valuation & Earnings
This table compares Ovid Therapeutics and Nuvation Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ovid Therapeutics | $7.25 million | 59.21 | -$17.41 million | ($0.29) | -7.93 |
| Nuvation Bio | $62.90 million | 27.15 | -$204.63 million | ($0.43) | -11.41 |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Ovid Therapeutics and Nuvation Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ovid Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
| Nuvation Bio | 2 | 1 | 8 | 0 | 2.55 |
Ovid Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 122.83%. Nuvation Bio has a consensus price target of $12.50, indicating a potential upside of 154.84%. Given Nuvation Bio’s higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Ovid Therapeutics.
Volatility & Risk
Ovid Therapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Institutional & Insider Ownership
72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Ovid Therapeutics and Nuvation Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ovid Therapeutics | -240.11% | -22.51% | -18.67% |
| Nuvation Bio | -102.06% | -44.10% | -23.80% |
Summary
Ovid Therapeutics beats Nuvation Bio on 9 of the 15 factors compared between the two stocks.
About Ovid Therapeutics
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
About Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
